Annual Scientific Gathering

Our Annual Scientific Gathering convenes preeminent scientists and clinicians, as well as patients, brain tumor advocacy groups, industry leaders and government officials to advance innovations in brain cancer research and foster strategic collaboration.

September 29 - 30, 2011 - Sausalito, CA

Thursday, September 29

8:30 - 8:45          Welcome Remarks and Introductions

                              Max Wallace
                              CEO, Accelerate Brain Cancer Cure

8:45 - 9:30          Conversation with Phillipe Bishop, Vice President, Genentech

10:00 -10:30       Mechanisms of Resistance to Targeted Therapy

                              Web Cavanee
                              Director, Ludwig Institute for Cancer Research               

10:30 -11:30       Therapeutic Potential of Targeting IDH1

                              Hai Yan
                              Assistant Professor of Pathology, Molecular, Duke University
                              Yu Xiong
                              William R. Kennen, Jr. Professor, UNC-Chapel Hill

11:30 - Noon       Non-Stem Cell Origin for Oligodendroglioma

                               Bill Weiss
                               Professor, Dept. of Neurology, Pediatrics and Neurological Surgery, UCSF

Noon - 1:00         Lunch with talk by Chris O'Neill, Google

1:00 - 2:30           Immune Therapy Approaches

                                Charles Cobbs
                                California Pacific Medical Center

                                Duane Mitchell
                                Assistant Professor, Duke University

                                Amy Heimberger
                                Associate Professor, MD Anderson Cancer Center

2:45 - 3:45           Air Game

                                 Development of Mebendazole and Approved Drugs to Treat Gliomas
                                 Greg Riggins
                                 Director, Division of Neurosurgery Research, Johns Hopkins University

                                 Clinical Trial Update
                                 Harry Gruber
                                 CEO, Tocagen, Inc.

                                 Update on Inhibition of Vasculogenesis Combined with Tumor Irradiation
                                 Martin Brown
                                 Professor, Stanford University

3:45 - 4:15          Time of Our Lives

                                Alex Harris
                                Founder, Center for Documentary Studies                    

Friday, September 30

8:30 – 9:00          The Case for Studying Chordoma

                               Josh Sommer
                               Executive Director, Chordoma Foundation

9:00 – 9:30         Chromosome 5p/9p/20q/8q Germline Alterations in Glioma

                               Bob Jenkins
                               Professor, Mayo Clinic
                              
9:45 – 10:15       Identification and Development of Synergistic Combination Therapies for GBM

                               Jim Olson
                               Principal Investigator, Fred Hutchinson Cancer Research Center                         

10:15 – 10:30     Combination High Throughput Screening to Identify Novel Cancer Targets and Therapeutics

                              Ricky Rickles
                              Director, Zalicus

10:30 -11:00       Developments in Industry

                               Raj Chopra
                               Vice President, Translational Research, Celgene

11:00 - 11:30      Closing Remarks

                              Max Wallace
                              CEO, Accelerate Brain Cancer Cure